新型恶唑烷酮类药物瑞巴唑利（RBX 7644）与其他药物相比的抗肺炎球菌和抗葡萄球菌活性。
Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
作者信息
Hoellman Dianne B, Lin Gengrong, Ednie Lois M, Rattan Ashok, Jacobs Michael R, Appelbaum Peter C
机构信息
Department of Pathology, Hershey Medical Center, Pennsylvania 17033, USA.
出版信息
Antimicrob Agents Chemother. 2003 Mar;47(3):1148-50. doi: 10.1128/AAC.47.3.1148-1150.2003.
Abstract
For 260 pneumococcal and 266 staphylococcal strains, ranbezolid MICs ranged from < or =0.06 to 4 micro g/ml. The MICs for pneumococci were similar irrespective of the strains' beta-lactam, macrolide, or quinolone susceptibilities, and ranbezolid MICs for coagulase-negative staphylococci were lower than those for Staphylococcus aureus. Ranbezolid was bacteriostatic against pneumococci. Ranbezolid MICs were similar to or lower than those of linezolid. Vancomycin and quinupristin-dalfopristin were also very active.
摘要
对于260株肺炎球菌和266株葡萄球菌菌株，瑞他唑啉的最低抑菌浓度（MIC）范围为≤0.06至4μg/ml。无论肺炎球菌菌株对β-内酰胺类、大环内酯类或喹诺酮类药物的敏感性如何，其MIC相似，凝固酶阴性葡萄球菌的瑞他唑啉MIC低于金黄色葡萄球菌。瑞他唑啉对肺炎球菌具有抑菌作用。瑞他唑啉的MIC与利奈唑胺相似或更低。万古霉素和奎奴普丁-达福普汀也非常有效。
相似文献
1
Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
Antimicrob Agents Chemother. 2003 Mar;47(3):1148-50. doi: 10.1128/AAC.47.3.1148-1150.2003.
2
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
Antimicrob Agents Chemother. 2003 Mar;47(3):1143-7. doi: 10.1128/AAC.47.3.1143-1147.2003.
3
Effect of oxazolidinone, RBx 7644 (ranbezolid), on inhibition of staphylococcal adherence to plastic surfaces.
J Chemother. 2008 Aug;20(4):420-7. doi: 10.1179/joc.2008.20.4.420.
4
Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
J Antimicrob Chemother. 1999 Apr;43(4):569-73. doi: 10.1093/jac/43.4.569.
5
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33. doi: 10.1128/AAC.49.8.3325-3333.2005.
6
Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Antimicrob Agents Chemother. 2004 Oct;48(10):4027-32. doi: 10.1128/AAC.48.10.4027-4032.2004.
7
Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents.
J Antimicrob Chemother. 2002 Jul;50(1):95-100. doi: 10.1093/jac/dkf080.
8
In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria.
Int J Antimicrob Agents. 2004 Oct;24(4):369-73. doi: 10.1016/j.ijantimicag.2004.04.012.
9
Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Antimicrob Agents Chemother. 2004 Oct;48(10):4033-6. doi: 10.1128/AAC.48.10.4033-4036.2004.
10
In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1999 Jun;34(2):119-22. doi: 10.1016/s0732-8893(99)00016-4.
引用本文的文献
1
Comparative Assessment of Docking Programs for Docking and Virtual Screening of Ribosomal Oxazolidinone Antibacterial Agents.
Antibiotics (Basel). 2023 Feb 24;12(3):463. doi: 10.3390/antibiotics12030463.
2
Strategies to Improve the Potency of Oxazolidinones towards Bacterial Biofilms.
Chem Asian J. 2022 Jun 1;17(11):e202200201. doi: 10.1002/asia.202200201. Epub 2022 Apr 13.
3
In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7134-7145. doi: 10.1128/AAC.00453-16. Print 2016 Dec.
4
Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.
Antimicrob Agents Chemother. 2009 Apr;53(4):1427-33. doi: 10.1128/AAC.00887-08. Epub 2008 Dec 15.
5
Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.
Drugs. 2007;67(16):2355-82. doi: 10.2165/00003495-200767160-00005.
6
Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.
Antimicrob Agents Chemother. 2006 Jun;50(6):2042-9. doi: 10.1128/AAC.01411-05.
7
Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Antimicrob Agents Chemother. 2005 Oct;49(10):4210-9. doi: 10.1128/AAC.49.10.4210-4219.2005.
8
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33. doi: 10.1128/AAC.49.8.3325-3333.2005.
9
Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry.
J Antimicrob Chemother. 2005 Aug;56(2):331-6. doi: 10.1093/jac/dki217. Epub 2005 Jun 24.
10
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Antimicrob Agents Chemother. 2005 Apr;49(4):1468-76. doi: 10.1128/AAC.49.4.1468-1476.2005.
本文引用的文献
1
In vitro activity of linezolid against staphylococci.
Clin Microbiol Infect. 2000 Jun;6(6):331-3. doi: 10.1046/j.1469-0691.2000.006006331.x.
2
In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.
J Antimicrob Chemother. 2001 Jan;47(1):77-81. doi: 10.1093/jac/47.1.77.
3
Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
J Antimicrob Chemother. 2000 Dec;46(6):931-40. doi: 10.1093/jac/46.6.931.
4
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.
Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13. doi: 10.1128/AAC.44.12.3408-3413.2000.
5
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
J Antimicrob Chemother. 2000 Sep;46(3):347-50. doi: 10.1093/jac/46.3.347.
6
Oxazolidinones: a review.
Drugs. 2000 Jan;59(1):7-16. doi: 10.2165/00003495-200059010-00002.
7
Optimal treatment of complicated skin and skin structure infections.
J Antimicrob Chemother. 1999 Sep;44 Suppl A:19-23. doi: 10.1093/jac/44.suppl_1.19.
8
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.
Antimicrob Agents Chemother. 1999 Aug;43(8):1901-8. doi: 10.1128/AAC.43.8.1901.
9
In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
Diagn Microbiol Infect Dis. 1999 Jun;34(2):119-22. doi: 10.1016/s0732-8893(99)00016-4.
10
The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.
Am J Med. 1998 May 29;104(5A):7S-10S. doi: 10.1016/s0002-9343(98)00149-1.
Zotero 插件